Home // Company // Sustainability // Planet // Lean Six Sigma Sustainability

Enabling Sustainability Home // Sustainability // Preserving the Planet

Advanced Composite Materials from PolyOne Bringing Innovation and Sustainability to Transportation Industry PolyOne Drives Textile Industry Sustainability and Innovation with Fiber Colorant Technology

General Purposes The general purposes of the Committee are to: • Develop the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers and, further, to assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of remuneration throughout the Company, including benefits and perquisites of executive officers of the Company and any other employees designated by the Committee as key employees of the Company and its subsidiaries; • Discharge similar responsibilities with respect to the remuneration of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices. Review and Discuss the CD&A and Compensation Committee Report. • With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. 4 Board Reports and Annual Evaluation. • Regularly report the Committee’s activities and any recommendations to the Board in such manner and at such times as the Committee or the Board deems appropriate. • Conduct an annual evaluation of the Committee’s performance. Independence Assessment of Outside Advisers • The Committee may select a compensation consultant, legal counsel or other adviser to the Committee or receive advice from a compensation consultant, legal counsel or other adviser (other than in-house legal counsel or any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for a particular company or that is customized based on parameters that are not developed by the compensation consultant, and about which the compensation consultant does not provide advice) only after taking into consideration all factors relevant to that person’s independence from management, including the following: • the provision of other services to the Company by the employer of the compensation consultant, legal counsel or other adviser; 5 • the amount of fees received from the Company by the employer of the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the employer of the compensation consultant, legal counsel or other adviser; • the policies and procedures of the employer of the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest; • any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee; • any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and • any business or personal relationship of the compensation consultant, legal counsel, other adviser or the employer of the adviser with an executive officer of the Company. • The Committee shall evaluate whether any compensation consultant retained or to be retained by it has any conflict of interest in accordance with Item 407(e)(3)(iv) of Regulation S-K.

Healthcare use limitations apply—see below. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection.

Healthcare use limitations apply—see below * Available only in North America ** Available on request Copyright © 2022, Avient Corporation. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection.

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Healthcare use limitations apply—see below. Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection.

Values reported as “typical” or stated without a range do not state minimum or maximum properties; consult your sales representative for property ranges and min/max specifications. AVIENT MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, either with respect to the information or products reflected by the information. To learn more about our advanced composite solutions, contact Avient at 1.844.4AVIENT or visit www.avient.com.